Charlotte M. Huijts
Amsterdam, NH 1081HV, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
Journal: Cancer immunology, immunotherapy : CII
Published: September 22, 2018
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.
Journal: Cancer immunology, immunotherapy : CII
Published: June 06, 2018
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: February 13, 2018
Immunological effects of everolimus in patients with metastatic renal cell cancer.
Journal: International journal of immunopathology and pharmacology
Published: October 10, 2017
The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer.
Journal: Immunobiology
Published: October 05, 2016
Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer.
Journal: Experimental & molecular medicine
Published: March 07, 2016
Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.
Journal: Clinical immunology (Orlando, Fla.)
Published: January 05, 2016
Response to Comment on "mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells".
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: November 22, 2015
mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: October 24, 2014
Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.
Journal: Clinical immunology (Orlando, Fla.)
Published: September 15, 2014
Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.
Journal: Current drug targets
Published: August 25, 2014
Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 14, 2014
Last Updated: 09/26/2026